Northwest & Ethical Investments L.P. Purchases New Position in IQVIA Holdings Inc. (NYSE:IQV)

Northwest & Ethical Investments L.P. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 13,400 shares of the medical research company’s stock, valued at approximately $3,175,000.

Several other large investors have also added to or reduced their stakes in IQV. Vinva Investment Management Ltd increased its stake in IQVIA by 14.1% in the 3rd quarter. Vinva Investment Management Ltd now owns 8,324 shares of the medical research company’s stock valued at $1,954,000 after buying an additional 1,026 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after buying an additional 39,772 shares during the last quarter. Castle Hook Partners LP purchased a new stake in IQVIA in the 3rd quarter valued at about $39,253,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in IQVIA by 34.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 100,603 shares of the medical research company’s stock valued at $23,840,000 after buying an additional 25,778 shares during the last quarter. Finally, Providence Capital Advisors LLC increased its stake in IQVIA by 1.5% in the 3rd quarter. Providence Capital Advisors LLC now owns 22,091 shares of the medical research company’s stock valued at $5,235,000 after buying an additional 324 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.1 %

Shares of NYSE:IQV opened at $201.43 on Friday. The firm has a fifty day moving average price of $219.50 and a two-hundred day moving average price of $226.40. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a market cap of $36.56 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 2.07 and a beta of 1.51.

Analyst Upgrades and Downgrades

IQV has been the subject of several research analyst reports. Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Truist Financial decreased their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. TD Cowen decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.